An online survey of 50 qualified KOLs (25 US, 25 EU across EU5 countries)—vetted by at least three activities like journal publications, clinical trials, and guidelines—reveals KOLs' openness to sharing insights for greater impact. Veeva's AI-powered solution transforms this opportunity by accelerating medical insights analysis, as demonstrated by BridgeBio's faster launch readiness. It streamlines management of insights from capture to action, enabling biopharma teams to turn raw KOL data into strategic impact through intelligent automation, real-time processing, and seamless integration—driving quicker decisions and enhanced collaboration.

Join for free to read